Categories: HEALTH

BioNTech’s BNT-211 for testicular cancer: Likelihood of approval

In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.

BNT-211 Overview

BNT-211 is being developed to treat a variety of solid tumors, including endometrial cancer, sarcoma, testicular cancer, ovarian cancer, fallopian tube cancer, peritoneal tumors, non-small cell lung cancer, gastric cancer, and uterine cancer. T-cell immunotherapy treats cancer by engineering chimeric antigen receptors (CARs). The therapeutic candidate was developed using Unicell technology, which enables high-throughput cloning and validation of human T cell receptors (TCRs) from single antigen-reactive T lymphocytes. The therapy targets cells that express claudin 6.

BioNTech Overview

BioNTech is a biotechnology company developing immunotherapies for cancer and infectious diseases. The company is investigating mRNA therapeutics, engineered cell and gene therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate cancer, head and neck cancer, ovarian cancer, pancreatic cancer and Triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, malaria, hepatitis B, influenza and COVID-19. BioNTech uses the FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It partners with Genentech Inc., Pfizer Inc., Genmab AS and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

For complete information on BNT-211 drug-specific PTSR and LoA scores, purchase the report here.

Desde

The gold standard in business intelligence.

GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.

GlobalData, a leading provider of industry intelligence, provided the underlying data, research and analysis used to write this article.

GlobalData’s Likelihood of Approval Analysis tool dynamically assesses and predicts the likelihood of a drug advancing to the next phase of clinical development (PTSR), as well as the likelihood of drug approval (LoA). This is based on a combination of machine learning and proprietary algorithms used to process data points from various databases in GlobalData’s Pharmaceutical Intelligence Center.

Source link

Admin